dc.contributor.author | Fernandez Rivera, Constantino | |
dc.contributor.author | Calvo Rodríguez, María | |
dc.contributor.author | Poveda, José Luís | |
dc.contributor.author | Pascual, Julio | |
dc.contributor.author | Crespo, Marta | |
dc.contributor.author | Gomez, Gonzalo | |
dc.contributor.author | Cabello Pelegrin, Sheila | |
dc.contributor.author | Paul, Javier | |
dc.contributor.author | Lauzurica, Ricardo | |
dc.contributor.author | Perez Mir, Mònica | |
dc.contributor.author | Moreso, Francesc | |
dc.contributor.author | Perelló, Manel | |
dc.contributor.author | Andres, Amado | |
dc.contributor.author | González, Esther | |
dc.contributor.author | Fernandez, Ana | |
dc.contributor.author | Mendiluce, Alicia | |
dc.contributor.author | Fernández Carbajo, Beatriz | |
dc.contributor.author | Sanchez Fructuoso, Ana | |
dc.contributor.author | Calvo, Natividad | |
dc.contributor.author | Suarez, Alejandro | |
dc.contributor.author | Bernal Blanco, Gabriel | |
dc.contributor.author | Osuna, Antonio | |
dc.contributor.author | Ruiz-Fuentes, M Carmen | |
dc.contributor.author | Melilli, Edoardo | |
dc.contributor.author | Montero Perez, Nuria | |
dc.contributor.author | Ramos, Ana | |
dc.contributor.author | Fernández, Beatriz | |
dc.contributor.author | López, Verónica | |
dc.contributor.author | Hernandez, Domingo | |
dc.contributor.author | Better study | |
dc.date.accessioned | 2024-02-19T15:32:25Z | |
dc.date.available | 2024-02-19T15:32:25Z | |
dc.date.issued | 2021-12-17 | |
dc.identifier.other | http://hdl.handle.net/10668/19932 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/18521 | |
dc.description.abstract | Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs. PR-Tac (61% increase; P | |
dc.language.iso | eng | |
dc.type.hasVersion | VoR | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | bioavailability | |
dc.subject | clinical practice | |
dc.subject | pharmacokinetics | |
dc.subject | renal transplantation | |
dc.subject | tacrolimus | |
dc.subject | treatment failure | |
dc.subject.mesh | Biological Availability | |
dc.subject.mesh | Drug Administration Schedule | |
dc.subject.mesh | Graft Rejection | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunosuppressive Agents | |
dc.subject.mesh | Kidney Transplantation | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Tacrolimus | |
dc.subject.mesh | Transplant Recipients | |
dc.title | Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study. | |
dc.type | research article | |
dc.rights.license | Attribution-NonCommercial 4.0 International | * |
dc.identifier.pubmedID | 34851532 | es_ES |
dc.format.volume | 36 | es_ES |
dc.format.number | 3 | es_ES |
dc.format.page | e14550 | es_ES |
dc.identifier.doi | 10.1111/ctr.14550 | |
dc.identifier.e-issn | 1399-0012 | es_ES |
dc.identifier.journal | Clinical transplantation | es_ES |
dc.rights.accessRights | open access | es_ES |